Trialect

Active

Notice of Special Interest (NOSI): Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Risk

National Institutes of Health

The purpose of this notice of special interest (NOSI) is to solicit submission of innovative epidemiologic research designed and focused on facilitating and enhancing our understanding of the impact of long-term incretin mimetic use on cancer risk and outcomes among individuals with and without comorbid conditions. Cancer types vary in latency after exogenous exposure(s). As such, latency/temporal issues (long term exposure to incretin mimetics and follow-up time) must be critically considered in proposed projects. A minimum latency period for incretin mimetic use of one (1) year is required. In this NOSI we seek applications using large clinical data sets.

This proposed NOSI complements the molecular focus of PAR-23-279 and PAR-23-280 “Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics” which solicit mechanistic investigations related to incretin mimetics. Investigations in response to the proposed NOSI align with three domains across the cancer continuum (Etiology, Prevention, and Survivorship).

Investigators are strongly encouraged to use one of various epidemiologic study designs in response to this NOSI. These may include leveraging existing population-based data sources, such as cohorts and registries, and data from available randomized clinical trials. Applicants are also encouraged to incorporate real-world data (e.g., electronic health records) when possible, or may propose new data collection as warranted. Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the requirements as outlined in the NIH Grants Policy Statement. Upon approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.

This NOSI expires May 09, 2026.

NOT-CA-24-037